AGIO moved above its 50-day moving average on October 19, 2026 date and that indicates a change from a downward trend to an upward trend. In 46 of 54 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 85%.
The Momentum Indicator moved above the 0 level on October 19, 2026. You may want to consider a long position or call options on AGIO as a result. In 82 of 101 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 81%.
The Moving Average Convergence Divergence (MACD) for AGIO just turned positive on October 19, 2026. Looking at past instances where AGIO's MACD turned positive, the stock continued to rise in 41 of 51 cases over the following month. The odds of a continued upward trend are 80%.
Following a +6.53% 3-day Advance, the price is estimated to grow further. Considering data from situations where AGIO advanced for three days, in 229 of 298 cases, the price rose further within the following month. The odds of a continued upward trend are 77%.
The RSI Indicator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.
The Stochastic Oscillator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where AGIO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 75%.
AGIO broke above its upper Bollinger Band on October 19, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for AGIO entered a downward trend on October 14, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron Valuation Rating of 25 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.163) is normal, around the industry mean (2.988). P/E Ratio (-5.304) is within average values for comparable stocks, (-1.158). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (123.903) among similar stocks. P/S Ratio (19.685) is also within normal values, averaging (438.009).
The Tickeron Price Growth Rating for this company is 41 (best 1 - 100 worst), indicating steady price growth. AGIO’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 99 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. AGIO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an uptrend is expected.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 22 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
TPST may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Momentum Indicator moved below the 0 level on October 06, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on TPST as a result. In 72 of 80 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
The Moving Average Convergence Divergence Histogram (MACD) for TPST turned negative on September 24, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 41 similar instances when the indicator turned negative. In 39 of the 41 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
TPST moved below its 50-day moving average on September 23, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where TPST declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for TPST entered a downward trend on October 21, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron PE Growth Rating for this company is 10 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 16 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-8.093) is normal, around the industry mean (2.988). P/E Ratio (-0.142) is within average values for comparable stocks, (-1.158). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (123.903) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (438.009).
The Tickeron Price Growth Rating for this company is 93 (best 1 - 100 worst), indicating slightly worse than average price growth. TPST’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. TPST’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
AGIO | TPST | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 33 | 91 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 25 Undervalued | 16 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 97 | 100 | |
PRICE GROWTH RATING 1..100 | 41 | 93 | |
P/E GROWTH RATING 1..100 | 99 | 10 | |
SEASONALITY SCORE 1..100 | 50 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
TPST's Valuation (16) in the Pharmaceuticals Major industry is in the same range as AGIO (25) in the Biotechnology industry. This means that TPST’s stock grew similarly to AGIO’s over the last 12 months.
TPST's Profit vs Risk Rating (100) in the Pharmaceuticals Major industry is in the same range as AGIO (100) in the Biotechnology industry. This means that TPST’s stock grew similarly to AGIO’s over the last 12 months.
AGIO's SMR Rating (97) in the Biotechnology industry is in the same range as TPST (100) in the Pharmaceuticals Major industry. This means that AGIO’s stock grew similarly to TPST’s over the last 12 months.
AGIO's Price Growth Rating (41) in the Biotechnology industry is somewhat better than the same rating for TPST (93) in the Pharmaceuticals Major industry. This means that AGIO’s stock grew somewhat faster than TPST’s over the last 12 months.
TPST's P/E Growth Rating (10) in the Pharmaceuticals Major industry is significantly better than the same rating for AGIO (99) in the Biotechnology industry. This means that TPST’s stock grew significantly faster than AGIO’s over the last 12 months.
| AGIO | TPST | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 76% | 2 days ago 85% |
| Stochastic ODDS (%) | 2 days ago 82% | 2 days ago 81% |
| Momentum ODDS (%) | 2 days ago 81% | 2 days ago 90% |
| MACD ODDS (%) | 2 days ago 80% | 2 days ago 90% |
| TrendWeek ODDS (%) | 2 days ago 79% | 2 days ago 90% |
| TrendMonth ODDS (%) | 2 days ago 81% | 2 days ago 90% |
| Advances ODDS (%) | 2 days ago 77% | N/A |
| Declines ODDS (%) | 10 days ago 75% | 2 days ago 90% |
| BollingerBands ODDS (%) | 2 days ago 74% | 2 days ago 80% |
| Aroon ODDS (%) | 2 days ago 73% | 2 days ago 89% |
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
AGIO’s FA Score shows that 1 FA rating(s) are green while TPST’s FA Score has 2 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
AGIO’s TA Score shows that 4 TA indicator(s) are bullish while TPST’s TA Score has 3 bullish TA indicator(s).
AGIO (@Biotechnology) experienced а +20.05% price change this week, while TPST (@Biotechnology) price change was -17.57% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -1.10%. For the same industry, the average monthly price growth was -18.18%, and the average quarterly price growth was -15.20%.
AGIO is expected to report earnings on Nov 05, 2026.
TPST is expected to report earnings on Nov 04, 2026.
Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
A.I.dvisor indicates that over the last year, AGIO has been loosely correlated with AXON. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if AGIO jumps, then AXON could also see price increases.
| Ticker / NAME | Correlation To AGIO | 1D Price Change % | ||
|---|---|---|---|---|
| AGIO | 100% | +1.47% | ||
| AXON - AGIO | 45% Loosely correlated | +2.54% | ||
| NRIX - AGIO | 45% Loosely correlated | -0.31% | ||
| TPST - AGIO | 40% Loosely correlated | -9.13% | ||
| VCYT - AGIO | 38% Loosely correlated | +3.19% | ||
| CNTN - AGIO | 37% Loosely correlated | +11.56% | ||
More | ||||